Skip to content

Total Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$9.45B+15.8%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$101.92M+158%
IQVIA logo
IQVIAIQV
$23.33B+9.3%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s total liabilities?
Apogee Therapeutics, Inc. (APGE) reported total liabilities of $37.86M in Q1 2026.
How has Apogee Therapeutics, Inc.'s total liabilities changed year-over-year?
Apogee Therapeutics, Inc.'s total liabilities decreased by 7.2% year-over-year, from $40.8M to $37.86M.
What is the long-term trend for Apogee Therapeutics, Inc.'s total liabilities?
Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s total liabilities has grown at a 49.4% compound annual growth rate (CAGR), from $9.98M to $33.25M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.